| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Z-DL-Pro-OH is classified as a protected amino acid derivative and a proline analogue. It does not have a specific biological receptor target. Its primary application is in peptide synthesis for introducing proline residues. The Z group provides orthogonal N-terminal protection removable by hydrogenolysis. The cyclic structure of proline imparts conformational constraints to peptides.
|
|---|---|
| ln Vitro |
In vitro activity for Z-DL-Pro-OH is primarily as a peptide synthesis reagent. Amino acid derivatives have been studied as ergogenic supplements. Z-DL-Pro-OH itself is not directly biologically active. Its utility is in preparing proline-containing peptides for subsequent biological evaluation. The proline residue can induce turns and influence peptide conformation.
|
| ln Vivo |
In vivo activity data for Z-DL-Pro-OH as a standalone compound is not applicable. It is a protected amino acid building block used in research. Peptides synthesized using this building block may be evaluated in animal models. The Z protecting group is typically removed before any biological testing.
|
| Enzyme Assay |
In vitro protocols for Z-DL-Pro-OH involve its use in peptide synthesis. The compound is activated using coupling reagents and coupled to a growing peptide chain. The Z group is removed by catalytic hydrogenolysis. Purity is typically high. Coupling efficiency is monitored by standard methods.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Z-DL-Pro-OH as it is a synthesis building block. Proline-containing peptides synthesized using this reagent can be tested in cell culture. Peptides are dissolved in DMSO or appropriate buffers and added to cells at concentrations of 0.1-100 µM. Incubation is typically 24-72 hours.
|
| Animal Protocol |
Animal studies with Z-DL-Pro-OH are not conducted directly. Peptides containing proline residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Z-DL-Pro-OH as a standalone compound is not applicable. The compound has a molecular weight of 249.26 g/mol and is a solid at room temperature. Storage is recommended in a cool, dry place. The Z group is removed by hydrogenolysis during peptide synthesis.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for Z-DL-Pro-OH. The compound is for research use only. Standard safety precautions should be observed. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Z-DL-Pro-OH (CAS#: 5618-96-2) is also known as N-Cbz-DL-proline, N-Carbobenzoxy-DL-proline, and 1-(((benzyloxy)carbonyl)amino)cyclopentane-1-carboxylic acid (for the proline analog). Its molecular formula is C13H15NO4. It is a protected DL-proline building block for peptide synthesis. It has no approved therapeutic indications.
|
| Molecular Formula |
C13H15NO4
|
|---|---|
| Molecular Weight |
249.2625
|
| Exact Mass |
249.1
|
| CAS # |
5618-96-2
|
| PubChem CID |
232388
|
| Appearance |
White to off-white powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
432.3±45.0 °C at 760 mmHg
|
| Flash Point |
215.3±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.582
|
| LogP |
1.17
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
312
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)COC(=O)N2CCCC2C(=O)O
|
| InChi Key |
JXGVXCZADZNAMJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H15NO4/c15-12(16)11-7-4-8-14(11)13(17)18-9-10-5-2-1-3-6-10/h1-3,5-6,11H,4,7-9H2,(H,15,16)
|
| Chemical Name |
1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid
|
| Synonyms |
DL-Cbz-Proline; Z-DL-Pro-OH; N-Cbz-DL-proline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~401.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0119 mL | 20.0594 mL | 40.1188 mL | |
| 5 mM | 0.8024 mL | 4.0119 mL | 8.0238 mL | |
| 10 mM | 0.4012 mL | 2.0059 mL | 4.0119 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
